Drugs Made In America Acquisition (DMAA) stock price is $10.89, up 0.09% on the day, as of Oct 1, 2026. It has a market cap of $335.55Mn and a P/E ratio of 52.32, and is classified in the Alternative Asset Managers industry (Financial Services sector).
Drugs Made In America Acquisition Corp is a blank check company incorporated in the Cayman Islands as an exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company has neither engaged in any operations nor generated any revenue to date. Based on its business activities, it is considered a shell company under the…
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | BLK | BlackRock, Inc. | 164.13 Bn | 24.52 | 6.01 | - |
| 2 | GLD | Spdr Gold Trust | 133.82 Bn | 5.94 | - | - |
| 3 | BX | Blackstone Inc. | 84.08 Bn | 25.39 | 5.22 | 13.19 Bn |
| 4 | BN | BROOKFIELD Corp /ON/ | 82.97 Bn | 63.38 | 1.08 | 14.71 Bn |
| 5 | KKR | KKR & Co. Inc. | 81.05 Bn | 27.04 | 3.80 | - |
| 6 | BAM | Brookfield Asset Management Ltd. | 71.64 Bn | 25.54 | 12.49 | 3.47 Bn |
| 7 | APO | Apollo Global Management, Inc. | 65.67 Bn | 37.95 | 1.83 | - |
| 8 | DMAA | Drugs Made In America Acquisition Corp. | 0.34 Bn | 52.32 | - | 0.00 Bn |